Tendon Healing

Scar, not regeneration. Tendon heals through sequential and overlapping phases of inflammation, proliferation and remodelling. Bone regenerates native tissue; tendon heals by scar, which never fully restores the structure or the biomechanical properties of healthy tendon.

How it differs from bone. Scar aside, the two tissues differ in three ways:

• Bone restores 100% of its strength; tendon plateaus at 60-80%
• Bone reconstitutes normal architecture; tendon remains disorganised
• Bone healing follows a predictable timeline; tendon healing is highly variable

A balance in both directions. Too little inflammation delays healing and leaves poor strength; too much produces excessive scarring and adhesions. Motion behaves the same way: too little allows adhesions and weak, disorganised healing, while too much causes gap formation and rupture.

The three phases overlap, and their timings vary with the tendon and the injury. Each sets what the repair can tolerate, which is why rehabilitation is timed to them.

View larger

Two overlapping mechanisms. Healing draws on cells from within the tendon (intrinsic) and from the tissues around it (extrinsic), and the balance between the two determines the functional outcome. They are overlapping mechanisms, not alternatives: extrinsic healing starts first and lays down the initial collagen matrix. The clinical aim is to shift the balance toward intrinsic healing, not to abolish extrinsic healing.

View larger

Intrinsic healing. Tenocytes within the tendon substance and cells of the epitenon surface proliferate and synthesise matrix directly at the injury site. The result is organised collagen aligned with the tendon axis, minimal adhesions and preserved gliding. The price is slower initial healing and dependence on an intact vascular supply, and the mechanism is vulnerable to complete rupture.

Extrinsic healing. The inflammatory response recruits fibroblasts from the peritendinous tissue (paratenon, synovial sheath and surrounding fascia), which invade the healing site and deposit scar matrix. It gives rapid mechanical strength and occurs even when the tendon is completely disrupted, but the collagen is disorganised and adhesions bind the tendon to the surrounding structures, costing it its glide. Adhesions are the main complication of flexor tendon repair.

Flexor tendon repair. The Duran, Kleinert, Indiana and Mayo protocols are all based on healing biology. Early motion in weeks 0-6 prevents adhesions during the proliferative phase, and loading stays protected until 6 weeks, when remodelling begins.

Achilles tendon repair. The rehabilitation follows the phases:

• Immobilisation in equinus for the first 2 weeks
• Controlled dorsiflexion from 2 weeks, in the proliferative phase
• Progressive loading from 6 weeks, in the remodelling phase
• Full weight-bearing by 8-12 weeks
• Return to sport at 6-9 months (60-80% strength restoration)

Rotator cuff repair. Strong initial fixation allows early passive motion, but active loading is avoided for the first 6 weeks, and progressive strengthening follows during remodelling from 6 weeks. Re-tear risk is highest in the first 3 months, the weak collagen III phase. Biological augmentation (PRP, patches) targets the proliferative phase.

Counselling. Healing never restores 100% of normal strength, so the re-rupture risk persists lifelong. Smoking cessation is essential and diabetes control critical (see Factors Affecting Healing), and early compliance with rehabilitation determines the final outcome.

Tendinopathy is failed healing, not tendinitis. The Cook and Purdam continuum describes three stages, potentially reversible early, with a degenerative endpoint:

• Reactive tendinopathy: a non-inflammatory proliferative cell and matrix response to acute overload. The tendon thickens to reduce stress, and the change is reversible if load is reduced.
• Tendon dysrepair: failed healing with greater matrix breakdown, more cells and early neovascularity. Some reversibility remains.
• Degenerative tendinopathy: areas of cell death and disorganised matrix with neovessels. It is largely irreversible and the substrate for spontaneous rupture.

Treatment follows the pathology. Because the problem is degeneration (tendinosis) and failed healing, not inflammation, first-line treatment is load management and progressive mechanotherapy (eccentric or heavy-slow-resistance loading) to stimulate tenocyte matrix remodelling. Anti-inflammatories and repeated corticosteroid injection give short-term analgesia but worsen tendon structure and increase rupture risk, so corticosteroid is reserved for short-term symptom control, with caution.

Growth factors released from platelets, inflammatory cells and the healing tissue's own cells orchestrate the process. Their roles explain the therapeutic targets and the augmentation strategies under investigation.

TGF-β. Transforming growth factor-beta is the most abundant growth factor in tendon healing, the β1 isoform in particular. It stimulates fibroblast proliferation and collagen synthesis, and high levels are associated with adhesion formation. Of its three isoforms, TGF-β1 is pro-fibrotic, TGF-β2 intermediate and TGF-β3 anti-scarring, so a potential target is to reduce TGF-β1 or supplement TGF-β3 to minimise scarring.

VEGF. Vascular endothelial growth factor is the master regulator of angiogenesis. It peaks at 1-2 weeks and is essential for delivering nutrients and cells. Its role is biphasic, beneficial early in healing and detrimental late in chronic tendinopathy, and anti-VEGF therapies have been investigated for chronic tendinopathy.

IGF-1. Insulin-like growth factor-1 promotes tenocyte proliferation and type I collagen synthesis, enhances matrix protein production and is anti-apoptotic, supporting cell survival. It is a component of growth hormone-stimulated healing.

PDGF. Platelet-derived growth factor is released from platelet alpha granules. It is chemotactic for fibroblasts and inflammatory cells, stimulates cell proliferation, and is a component of PRP preparations.

bFGF. Basic fibroblast growth factor stimulates fibroblast proliferation and angiogenesis, enhances collagen synthesis, and acts in matrix synthesis and remodelling. It improves tensile strength in animal models and has been investigated as a therapeutic agent.

View larger

View larger

Vascular supply. Better blood supply correlates with better healing, and compromised vascularity slows all phases. Avascular zone 2 flexor tendons heal poorly, and the Achilles watershed zone, 2-6 cm proximal to the insertion, ruptures frequently.

Zone. In the flexor tendons, zone 1 has good vascularity and favourable outcomes, and zones 3-5 have excellent vascularity and favourable outcomes. Zone 2, with poor vascularity and an enclosed sheath, has the worst (see the Zone 2 pearl above). Rehabilitation protocols must be zone-specific.

Repair quality. The size of the gap decides how the tendon heals. A gap of less than 3 mm heals as organised tendon with minimal adhesions (gap healing); a gap greater than 3 mm heals by proliferative healing, which requires extensive granulation tissue and forms adhesions. The strength of the repair decides the rehabilitation: a strong 4-strand core suture (40-60 N) allows early motion, while a weak 2-strand repair (20-30 N) requires longer immobilisation.

View larger

Age. Children and adolescents heal faster, with a better intrinsic response and lower adhesion rates. Older adults heal more slowly, with reduced cellularity and higher adhesion rates, and healing time increases by approximately 10% per decade after the age of 30.

Diabetes. Macrophage function is impaired, with a delayed M1-to-M2 transition, and tenocyte proliferation and collagen synthesis are reduced. Advanced glycation end products impair cross-linking, and re-rupture rates are higher, 2-3 times for the Achilles.

Smoking. Smoking impairs all phases of healing. Vasoconstriction reduces blood flow, carbon monoxide causes tissue hypoxia, and fibroblast proliferation and collagen synthesis are reduced. Cessation at least 4 weeks before surgery reduces complications.

Medications. NSAIDs may impair the early inflammatory phase, though the evidence is mixed (see Controversies and Areas of Uncertainty). Corticosteroids inhibit collagen synthesis and delay healing, and quinolone antibiotics are associated with tendon ruptures.

View larger

Same biology, different sites. The three-phase cascade is universal, but local anatomy, vascularity and mechanical demand make outcomes and rehabilitation differ markedly between tendons. The flexor tendon heals tendon-to-tendon within a synovial environment; the rotator cuff and the Achilles at its enthesis must regenerate a graded tendon-to-bone interface that is rarely fully restored.

The enthesis. A direct (fibrocartilaginous) enthesis is a graded transition of four zones:

1. Tendon proper - dense type I collagen and tenocytes
2. Uncalcified fibrocartilage - type II collagen and aggrecan; stress begins to dissipate here
3. Calcified fibrocartilage - separated from the uncalcified layer by the tidemark, an abrupt basophilic line
4. Bone, into which the calcified fibrocartilage blends

This soft-to-hard transition over a short distance minimises stress concentration at the interface.

View larger

Why tendon-to-bone repair re-tears. After repair, for instance of the rotator cuff to its footprint, the body does not recreate these zones. It heals by disorganised fibrovascular scar with Sharpey-like fibres anchoring tendon to bone, which is mechanically inferior. This is the biological reason tendon-to-bone repairs, the cuff above all in large or massive tears in older patients, re-tear so commonly, and why biological augmentation and graded-interface tissue engineering are active research areas.

View larger

View larger

Global Epidemiology

• Tendon and ligament injuries account for a substantial share of musculoskeletal presentations; overuse tendinopathy is estimated to underlie roughly 30% of running-related injuries, and lateral elbow tendinopathy affects up to 40% of tennis players (Sharma & Maffulli).
• Acute Achilles rupture incidence has risen in many high-income settings to the order of 20-30 per 100,000 person-years, concentrated in active middle-aged adults ("weekend warriors").
• Flexor tendon lacerations are predominantly young working-age males with sharp hand trauma; outcome is heavily zone- and rehabilitation-dependent worldwide.

Side-by-Side Guidance (Principles, Not Country Frames)

Registry and High-Level Evidence Notes

• There is no dedicated international tendon registry equivalent to arthroplasty registries (NJR, AJRR, AOANJRR, SHAR). Best evidence comes from condition-specific RCTs (e.g. PATH-2 for PRP) and large trauma databases.
• Achilles and rotator cuff cohorts within national audit and shoulder/elbow datasets consistently report re-rupture/re-tear as the dominant healing-failure endpoint, reinforcing that biology, not technique alone, limits outcomes.

High- vs Limited-Resource Practice Variation

• High-resource settings: ready access to hand therapy, ultrasound/MRI for integrity assessment, and structured early-motion protocols - the main determinants of good flexor and cuff outcomes.
• Limited-resource settings: where supervised therapy is scarce, simpler, more protective immobilization protocols may be chosen to reduce rupture risk, accepting a higher adhesion burden. Strong, reproducible repair constructs and clear patient self-rehabilitation instructions become even more important.
• Biologics (PRP, growth factors) are not a priority where evidence is weak and cost is high; investment in rehabilitation infrastructure yields greater returns on healing outcomes.

NSAIDs after tendon repair. Experimental work consistently shows that COX inhibitors impair early proliferative healing and reduce tensile strength, yet they remain widely used for analgesia and ectopic-ossification prophylaxis. The pragmatic position is short-course, minimal-dose NSAIDs, avoided during the first 1-2 weeks after a tendon repair, accepting that high-level human tendon-outcome data are lacking.

Biological augmentation (PRP, growth factors, stem cells). Despite a strong biological rationale, the best controlled data (PATH-2, for acute Achilles rupture) show no benefit of PRP. Heterogeneous preparations (leukocyte-rich versus leukocyte-poor, activated versus not, variable platelet concentration) make pooled interpretation difficult, and there is no consensus to use these routinely.

View larger

Inflammation: friend or foe? The older view that inflammation is purely harmful has shifted. The M1-to-M2 macrophage transition is now seen as essential for orderly healing, and excessive suppression of early inflammation may impair repair. The target is modulation, not abolition.

Operative versus non-operative Achilles management. Modern functional rehabilitation with early weight-bearing has narrowed the re-rupture gap between surgical and conservative care, shifting many units toward non-operative management for selected patients, a direct clinical application of loading biology.

Type III collagen: obstacle or scaffold? Persistent type III collagen is associated with weaker tissue, yet it is also the necessary early scaffold. Strategies aimed simply at suppressing type III risk destabilising early repair; the goal is timely conversion to type I and alignment, not the elimination of type III.